Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Industrifonden in connection with investment in Apica
Mandate

Vinge advises Industrifonden in connection with investment in Apica

June 29, 2011

Vinge has advised Stiftelsen Industrifonden in connection with an SEK 10 million investment in Apica. Apica tests, analyses, monitors and improves the performance of websites. The existing investor, KTH Chalmers Capital also participated in the issue which amounts in total to SEK 15 million. The funds will be used to finance the launch of Apica’s services in the US. Apica was founded in 2005 and has its head office in Stockholm and sales offices in Great Britain and the US.

Vinge’s team consisted of project manager Johan Larsson together with Tina Hård and Malin Buch. Johan Winnerbald was the responsible partner.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026